FreeTheAI

Ardelyx Real-World Study Shows IBSRELA Reduces Healthcare Resource Use in IBS-C Patients

BullishMedium impact
ARDX$3.28 0.31%

Ardelyx, Inc. (ARDX) presented real-world data at the American College of Gastroenterology 2026 meeting showing that adults with irritable bowel syndrome with constipation experienced fewer gastrointestinal healthcare visits after starting IBSRELA (tenapanor). In an observational study of 470 patients at a national gastroenterology practice, median annual GI-related visits dropped from 4.5 prior to starting the medication to 3.0 visits in the year following initiation.

Lowering healthcare utilization highlights the potential real-world value of IBSRELA in managing IBS-C, a chronic condition estimated to affect 12 million people in the United States. Reductions in healthcare visits occurred across various patient subgroups, including those who had previously tried other IBS-C medications, regardless of body mass index or underlying medical conditions.

Beyond the observational findings, the company highlighted the design of an ongoing Phase 3 clinical trial evaluating tenapanor in adults with chronic idiopathic constipation. Additional presentations by the company focus on the impact of IBS-C symptom burden on overall patient quality of life.

Key points

  • Median annual GI-related healthcare visits decreased from 4.5 to 3.0 after patients started IBSRELA.
  • The retrospective real-world analysis tracked 470 adult IBS-C patients at a national gastroenterology practice.
  • Significant visit reductions occurred across subgroups, including patients who previously tried other IBS-C treatments.
  • Ardelyx is also conducting an ongoing Phase 3 trial evaluating tenapanor for chronic idiopathic constipation.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the main results of the Ardelyx IBSRELA study?

The study of 470 patients showed median yearly GI-related healthcare visits fell from 4.5 before taking IBSRELA to 3.0 in the year after starting treatment.

What other condition is tenapanor being evaluated for?

Ardelyx is conducting an ongoing Phase 3 clinical trial evaluating tenapanor in adults with chronic idiopathic constipation.

How many people in the US are affected by IBS-C?

Irritable bowel syndrome with constipation is estimated to affect 12 million people in the United States.